Secretome Therapeutics, a clinical-stage biotechnology company pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the appointment of Marshelle Smith Warren, ...

The first trial, led by Dr. Sanjiv Shah, founder of the world's first dedicated clinical program for HFpEF at Northwestern University Feinberg School of Medicine, will evaluate STM-01 in patients with ...

Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A ...

WASHINGTON, March 24, 2026 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), the leading U.S. non-profit driving Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, ...

FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 /PRNewswire/ -- RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development ...

Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced its ...

DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment of underserved ...

PLANO, Texas, December 29, 2025--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac ...

London-Based drug firm, AstraZeneca has entered into a new field of developing drugs using proteins secreted by the cells called as "Secretome". It has signed a three-year contract with the newly ...

The MarketWatch News Department was not involved in the creation of this content. RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and ...